Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vinorelbine - Pierre Fabre

Drug Profile

Vinorelbine - Pierre Fabre

Alternative Names: KW-2307; Navelbine; NVB; Vinorelbine ditartrate; Vinorelbine tartrate

Latest Information Update: 19 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CNRS
  • Developer Amgen; Bristol-Myers Squibb; Centre Oscar Lambret; Pierre Fabre; UNICANCER; University of Washington
  • Class Antineoplastics; Small molecules; Vinca alkaloids
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Non-small cell lung cancer
  • Phase II Glioma; Mesothelioma
  • Phase I/II Solid tumours
  • No development reported Cervical cancer; Head and neck cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Small cell lung cancer
  • Discontinued Multiple myeloma

Most Recent Events

  • 07 Aug 2019 Pierre Fabre terminates phase II trial in Breast cancer in Spain (EudraCT2016-002674-12)
  • 20 Jun 2018 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (PO) (NCT03518606)
  • 01 Jun 2018 Adverse events and efficacy data from phase II NAVoTRIAL-3 trial in Nono-small cell lung cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top